secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001493152-22-021614
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q2 net loss $4.5M; launches Phase 2 Harmonic trial for LP-300 in never-smoker NSCLC
--------------------------------------------------------------------------------

- Net loss of $4.5M ($0.41 per share) vs $2.3M ($0.21) in Q2 2021; R&D spend increased to $3.0M from $1.2M.
- Cash, cash equivalents, and marketable securities $62.2M as of June 30, 2022, down from $79.6M a year ago; cash runway into 2025.
- Phase 2 Harmonic trial for LP-300 launched; enrollment begins Q3 2022; initial results expected Q4 2023.
- INDs for LP-184 and LP-284 planned for early 2023; Phase 1 trials for LP-184 (CNS + solid tumors) and LP-284 (NHL) anticipated in H1 2023.
- RADR platform now exceeds 21 billion data points; Dr. Maria Maccecchini elected to board of directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315222021614/0001493152-22-021614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315222021614/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-021614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer